Johnson & Johnson’s IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight
The FDA has approved Johnson & Johnson’s anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under... Read more.
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight
Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene... Read more.
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib)... Read more.
Haivision to Announce Second Quarter Fiscal 2025 Financial Results on June 11, 2025
MONTREAL, May 22, 2025 /PRNewswire/ – Haivision Systems Inc. (“Haivision“) (TSX: HAI), a leading global provider of mission critical, real-time... Read more.
M-tron Industries, Inc. to Host Investor Presentation followed by Annual Meeting of Stockholders on June 10, 2025
ORLANDO, Fla., May 22, 2025 /PRNewswire/ — M-tron Industries, Inc. (NYSE American: MPTI) (“Mtron” or the “Company”) today announced... Read more.
Servotronics Announces Important Development with the Annual Meeting of Shareholders
– Beaver Hollow Wellness has withdrawn its nominees for election to the Company’s Board of Directors, thus ending the proxy contest – – Vote now on... Read more.
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INDIANAPOLIS, May 22, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral... Read more.
Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
Data will be shared in two oral presentations, a poster and two online abstracts Highlights include a potential novel, all-oral therapy for AML; and Phase 2 data... Read more.
Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting
ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focuson advanced or metastatic patients with BRCA-1 and/or BRCA-2-deficient... Read more.
Novita Highlights Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at 2025 ASCO Annual Meeting
NEW YORK, May 22, 2025 /PRNewswire/ — Novita Pharmaceuticals, Inc. (“Novita”), a privately held, clinical-stage pharmaceutical company dedicated... Read more.